FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
 Securities Case - EconoTimes)
NEW YORK, Nov. 14, 2016 -- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national investor rights law firm, reminds investors that January 9, 2017 is the last day to file lead plaintiff papers in the securities lawsuit against Diplomat Pharmacy, Inc. (“Diplomat” or the “Company”) (NYSE:DPLO). The class action is on behalf of a class consisting of all persons who purchased or otherwise acquired Diplomat shares between October 9, 2014 and November 2, 2016 inclusive (the “Class Period”). Diplomat investors are encouraged to go to: http://www.scott-scott.com/cases/new/securities-fraud-litigation-3035-diplomat-pharmacy-inc-dplo.html
Diplomat is a specialty pharmacy that services patients with complex chronic diseases, including the dispensing, delivery, dosing and reimbursement of clinically intensive, high cost specialty drugs. Diplomat’s core revenues are driven by multi-year and life-long patient care to treat chronic conditions including oncology, immunology and hepatitis C, and as a specialty pharmacy the Company is liable for direct and indirect remuneration (“DIR fees”) to government agencies, payors and insurance companies.
The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company lacked adequate internal controls over its financial reporting; (2) as a result the Company could not adequately calculate DIR fees; (3) the Company’s hepatitis C segment was not performing as previously disclosed to investors; (4) and therefore, the Company had overstated its full-year 2016 guidance; and (5) that, as a result of the foregoing, Defendants’ statements about Diplomat’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
What You Can Do
If you purchased Diplomat shares, you may have legal claims against the Company. If you want to discuss filing lead plaintiff papers, or have questions about your legal rights, please contact attorney Joe Pettigrew at (619) 517-1129, or at [email protected].
About Scott + Scott, Attorneys at Law, LLP
Scott+Scott has significant experience prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm has offices in New York, London, Connecticut, California, and Ohio. Please visit www.scott-scott.com for more information about the firm.
CONTACT: Joe Pettigrew Scott+Scott, Attorneys at Law, LLP (619) 517-1129 [email protected]
